

Andrea Morandi studied Biotechnology (BSc) and Medical Biotechnology (MSc) at the University of Florence and gained his BSc in 2004 and MSc in 2006 both with honors. Immediately after the MSc, Andrea started a PhD on the role of Tyrosine Kinase Receptors in breast cancer. In 2007, he moved to the Institute of Cancer Research in London in the laboratory of Prof Clare Isacke where he investigated, first as visiting PhD student and then as a postdoctoral fellow, the role of the receptor tyrosine kinase RET in response and resistance to endocrine therapy in breast cancer.

In 2013, Andrea was awarded a *Fondazione Italiana per la Ricerca sul Cancro* Fellowship to return to Italy and in 2018 became Faculty at the University of Florence. He is now Associate Professor of Biochemistry at the University of Florence and leads the Tumor Biochemistry Lab. The focus of his laboratory is to understand the molecular and metabolic pathways that influence response and resistance to endocrine therapy, to identify innovative predictive markers or potential therapeutic target in hormone receptor positive breast cancer. In 2021 he was appointed member of the *Comitato Tecnico Sanitario* of the Ministry of Health.